Patents Examined by Li N Komatsu
  • Patent number: 11998609
    Abstract: Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: June 4, 2024
    Assignee: The Johns Hopkins University
    Inventors: Honggang Cui, Charles Williams Flexner, Maya Monroe, Han Wang
  • Patent number: 11958890
    Abstract: The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: April 16, 2024
    Assignee: LYSANDO AG
    Inventors: Manfred Biebl, Martin Griessl
  • Patent number: 11957691
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 16, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11951174
    Abstract: This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as SARS-CoV-1, SARS-CoV-2 or a variant thereof. It is contemplated that the polypeptide can be further linked to a compound, wherein the compound extends the serum half-life of the polypeptide.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: April 9, 2024
    Assignee: Singh Biotechnology, LLC
    Inventor: Sunanda Singh
  • Patent number: 11952405
    Abstract: Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or compsiring a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: April 9, 2024
    Assignee: MEMORAL SLOAN KETTERING CANCER CENTER
    Inventors: Alex Kentsis, Kavitha Ramaswamy, Lauren Marek
  • Patent number: 11945856
    Abstract: There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF? superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and/or cardiometabolic disease, bone damage, and/or low red blood cell levels (such as anemia).
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: April 2, 2024
    Assignee: 35PHARMA Inc.
    Inventors: Maureen O'Connor-McCourt, Vannakambadi K. Ganesh, Gilles Tremblay, Gauthier Schang
  • Patent number: 11932677
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: March 19, 2024
    Assignee: AliveGen Inc.
    Inventors: Hq Han, Xiaolan Zhou
  • Patent number: 11925672
    Abstract: The present invention provides a functional peptide having excellent antioxidant activity, the peptide having excellent biocompatibility and significantly better antioxidant activity than conventional GSHs in order to overcome the limitation of the weak antioxidant activity of existing peptides. The peptide of the present invention can promote antioxidant activity or effectively repair biological tissue or cell damage caused by reactive oxygen species generated due to oxidative stress. Therefore, the peptide having such antioxidant activity effectively acts on cell damage caused by oxidative stress, and can thus be used to prevent and repair cell damage.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: March 12, 2024
    Assignee: SEMPIO FOODS COMPANY
    Inventors: Dae Hee Lee, Haet Nim Um, Moon Kyung Jeong, Mi Na Hong, Jung Hee Park, Yong Hahk Park, Byung Serk Hurh
  • Patent number: 11918656
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: March 5, 2024
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Marie Lamothe
  • Patent number: 11891352
    Abstract: The present invention is directed to compounds of the general formula (I) and salts thereof wherein X? is halide, pseudohalide, sulphate, benzoate, acetate, trifluoroacetate, hydroxide, saccharinate or capsaicinate; R10 is hydrogen or C1-C10-alkyl; and R1-R9 independently are hydrogen, halogen, C1-C5-alkyl, C1-C4-alkoxy, C1-C20-alkoxycarbonyl. The invention is furthermore directed to a method for the preparation of these compounds. The compounds can be used as bitter substances in medicine, pharmaceutics and/or diagnostics. They can furthermore be used for the coupling to proteins and peptides by means of forming a peptide bond between the amino-group of the compounds of the present invention and a carboxyl-group of the protein or peptide.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 6, 2024
    Assignee: Julius-Maximilians-Universitaet
    Inventors: Lorenz Meinel, Tessa Luehmann, Martina Raschig
  • Patent number: 11872283
    Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: January 16, 2024
    Assignee: Hanmi Science Co., Ltd
    Inventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
  • Patent number: 11857609
    Abstract: The present disclosure relates to a method for treating diabetic macular edema (DME) and/or retinal vein occlusion (RVO) comprising administering to the retina of a patient in need thereof an effective amount of a caspase-9 signaling pathway inhibitor. The caspase-9 signaling pathway inhibitor may include a peptide caspase-9 inhibitor and/or may be conjugated to a cell-penetrating peptide. The present disclosure further includes pharmaceutical compositions including a caspase-9 signaling pathway inhibitor. The disclosure further relates to the use of such compositions in a method for treating DME and/or RVO.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: January 2, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Carol M. Troy, Ying Y. Jean
  • Patent number: 11844878
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: December 19, 2023
    Assignee: Allergan, Inc.
    Inventors: Jacob F. Pollock, Lauren E. Kokai, Cunqi Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
  • Patent number: 11844845
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: December 19, 2023
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 11833269
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 5, 2023
    Assignee: Allergan, Inc.
    Inventors: Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
  • Patent number: 11795200
    Abstract: A nano small peptide FG and its use in preparation of drugs for treating and preventing fundus vascular diseases are provided. The artificially synthesized nano small peptide has a molecular formula of X-FFVLKKNKAAKG (SEQ ID NO:1), wherein the X is dodecanoyl, tetradecanoyl, hexadecanoyl, or octadecanoyl group. The nano small peptide of the present invention can specifically select receptors to encapsulate sSema4D protein, and the concentration of sSema4D is effectively reduced, so that the sSema4D is unable to bind to any receptors, thus changing the shortcoming of few inhibitory targets of antibody drugs. The nano small peptide molecule with a simple structure can be mixed with antibody drugs without causing mutual immune reactions, so as to achieve the effect of reducing multiple pro-angiogenesis molecules.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: October 24, 2023
    Assignee: FUTU Biotech Co., Ltd.
    Inventors: Bo Hu, Yanan Li, Hao Wang, Lei Wang
  • Patent number: 11795201
    Abstract: Methods of treating or reducing the risk of obesity and/or obesity-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: October 24, 2023
    Assignee: University of Massachusetts
    Inventors: Yong-Xu Wang, Qingbo Chen
  • Patent number: 11786450
    Abstract: A fusion protein includes heat shock protein 10 and brazzein protein. The fusion protein has an enhanced anti-oxidation activity and skin cell proliferation effect. It can be used as a cosmetic composition for ameliorating skin wrinkles. The cosmetic composition including the fusion protein can be advantageously used in future as a material of a functional cosmetic product.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 17, 2023
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Hyun Kim, Tae Won Choi
  • Patent number: 11779531
    Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQ ID NOs: 1-16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C) The anti-inflammatory fragment is from a region of the proteins of SEQ ID NOs: 1-16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQ ID NOs: 71-221.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: October 10, 2023
    Assignee: NURITAS LIMITED
    Inventors: Nora Khaldi, Cyril Lopez, Alessandro Adelfio
  • Patent number: 11779633
    Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: October 10, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang Wei, Haruka Okamoto, Jesper Gromada, Samuel Davis, Andrew J. Murphy